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Abstract
The treatment of numerous disease states has become increasingly more complex and 
challenging, even as we come out with new pharmacological and technological advancements. It 
is well known that cancer is not one disease, but many diseases that progress and present new 
challenges with each patient. With this we present a novel design which uses biorthogonal 
chemistry and magnetic nanoparticles (MNP’s) to create a drug delivery system with the 
capability to deliver two drugs that are released at two different time points under the direction 
of a single trigger. This innovative combination of multiple advancements will allow for the 
treatment of normally resistant cancer phenotypes by rewiring the cell with one treatment, and 
then inducing apoptosis with the next, sequentially killing the targeted cell. Our system allows 
for a controllable, finely tuned delivery that can be targeted and imaged using MRI with our 
active MNP’s. The system has been tested with release kinetics using two florescent probes, and 
then later in vitro to confirm efficient delivery of the payload. This simple, non-invasive 
treatment allows for a much easier and effective dual drug delivery system. It was shown using 
triple negative breast cancer cell lines to be more effective than current therapeutic treatments 
and enhance the efficiency of the drugs, when used synergistically.  
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Introduction: Through the progression of many cancer types, biological changes occur 
throughout many parts of the genome that manipulate the cancer to resist numerous types of 
common therapeutic treatments. With this, many strategies have been theorized and attempted to 
fight this problem and propose new ways to deliver drugs1,2. It has been outlined by many 
sources including Woodcock et. al. that single dose treatments and many traditional drug 
therapies are becoming ineffective due to the complexity of new diseases, among these being 
cancer3. This brings about the need for potential therapies such as multidrug delivery, however, 
this also comes with many challenges such as an additional task for a patient, delivery of these 
drugs, and interactions between them. Furthermore, the side effects of chemotherapies are 
increased as well. Many delivery systems have been shown using methods with liposomes and 
micelles, for example, however there are many questions remaining on the efficiency and target 
efficacy of these methods to deliver multiple drugs in one platform. Due to this, we have 
implemented a system using magnetic nanoparticles (MNPs) with sequential release to deliver a 
multidrug cocktail into the cell. These MNPs allow for an image guided approach to therapy, 
along with their capability to load drugs, such that you can monitor the location and 
accumulation of drug in the patient4. MNPs also allow and extend the circulation time 
throughout the body, which gives a greater chance of uptake of the payload into the tumor5.  
Along with these MNPs, we have also employed the use of a special linker molecule6, which 
allows for a signal trigger molecule to release the drugs of multiple payloads at different times 
and provides a precise and highly controllable approach to the treatment of resistant disease 
types. While our initial study showed promising and successful results (N.M. Robertson, V.E. 
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LaMantia, M. V. Yigit, submitted), we herein explore additional chemotherapeutic agents to 
further expand the knowledge on this system.  
Materials & Methods: 
Nanoparticle drug delivery is a very advantageous system to use and has picked up much 
popularity due to their inherent properties of solubility and specific number of binding sites. 
Concurrently, we employed the specialized linker system to allow for ‘click and release’ 
activation of one of the drugs immediately and another over a long period. Our MNP’s are an 
MRI-active amine terminated dextran coated iron oxide nanoparticle. These were previously 
used for noninvasive MRI imaging of lymph node metastasis in breast cancer patients, and 
prepared using the same methods as described within7. The linker system utilizes a bioorthogonal 
trans-cyclooctene (TCO) linker molecule which has been explored in many different areas, 
however has never been used for a practical delivery system6. This system utilizes an inverse 
electron demand Diels-Alder reaction (IEDDA) between TCO and tetrazine8,9. This allows us to 
functionalize nanoparticles with molecules of choice containing the TCO in one of two 
orientations, one in the axial position and the other in the equatorial position. The drug that will 
be released first will be determined depending on which drug is in which orientation. The drug 
placed in the axial position has a 156 fold faster release, which is believed to be due to steric 
hindrance and bond placement in the equatorial position.9 The inherent IEDDA reaction allows 
for one molecule to be released immediately, followed by the other later. This becomes very 
useful for the treatment of resistant cancer types. This is because treatment in a sequential 
manner has found great promise. The activity of the first drug can rewire and reform the cancer 
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cell, after this the second drug can come in with a now more vulnerable cell and treat more 
effectively and kill the cell in a precise controlled manner. Whereas if these two drugs were 
added simultaneously, the treatment would not be effective1,10,11. The synthesis of these linkers 
and tetrazine are according to previous studies and can be found in the supplemental section 
below.  
To study this method, we first used fluorescent dyes attached to the nanoparticles, rather 
than drugs. Using FAM (lex 484, lem 517 nm), which was attached to the allylic position of the 
di-equatorial TCO (slow acting), and TAMRA (lex 550, lem 576 nm), which was coupled to the
di-axial TCO (fast acting) linker, we could see a distinct signal from each dye to determine
release kinetics. Fluorescent studies were done using the Fluorolog3 spectrofluorometer. 
Conjugation of the MNPs was performed as a mixture: 250 µL of raw MNPs from stock, 250 µL 
Sodium Citrate buffer (20 mM Sodium Citrate, 150 mM Sodium Chloride, pH 8.2), and 5 µL of 
each dye in a 10 mM concentration. This mixture was left to conjugate in the dark for at least 24 
hours. The mixture was then washed through a GE Healthcare PD-10 desalting column with 
Thermo Pack PBS buffer (100 mM PBS, 150 mM Sodium Chloride, pH 7.2). To show 
ratiometric loading, we conjugated 8 different sets of MNPs with various concentrations of each 
dye, from all TAMRA, to equal TAMRA-FAM, to all FAM. These were first imaged on the Bio-
Rad Chemidoc with channels for both dyes and an overlaying channel to view both 
simultaneously. To further monitor the release of the dyes, we utilized High Performance Liquid 
Chromatography (HPLC) to show release after addition of tetrazine. These were conducted using 
a Phenomenex, Luna 5u C18(2) 100A column. Buffer A (100 mM TEAB pH 7.4); Buffer B 
(100% acetonitrile). The purification was achieved using an 18-minute gradient of 0-90% Buffer 
B.
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Cell culture of MDA-MB-231 cells were obtained from the American Type Culture 
Collection (ATCC). These cells were cultured in Dulbecco’s Modified Eagles Medium 
(DMEM). Media for the cells was supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. Ultrapure RNase-free water was used in all in vitro studies. All cells 
were cultured at 37 °C in a humidified incubator supplemented with 5% CO2 per to suppliers’ 
instructions. 
For microscopy studies, ~1,000 cells were plated on MatTek glass bottom plates for 24 
hours. These cells were then treated with ~534 nM (60 μg Fe/mL), 100 µL of the stock 
conjugated MNPs, and incubated for another 24 hours. The cells were washed and the medium 
was replaced with fresh DMEM 4 hours prior to confocal microscopy studies. The respective 
fluorescent channels were monitored throughout the study. We used the Zeiss LSM 710 Pascal 
laser confocal microscope (Carl Zeiss Microscopy, Thornwood, NY, USA) and analyzed using 
the Zeiss ZEN 2012 Confocal Microscopy Software for this study. 
For cell viability, we used the previously well documented colorimetric MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay4,12,13. On the first day of the study, 
using a 96-well format, ~100 cells were plated per well in 100 µL of DMEM and incubated for 
24 hr. Day two, the cells were introduced to 5 µL of the stock MNP constructs (final 
concentration of ~508 nM MNPs, 57 μg Fe/mL) and incubated for an additional 24 hr. On day 3, 
the medium was removed and the cells were treated with 10 µM (1 µL of a 1 mM stock) of 
tetrazine in 100 µL of fresh DMEM and incubated for 32 hr. On the final day, the medium was 
removed, and cells were incubated with 100 µL of MTT solution (0.6 mg/mL in DMEM) per 
well for 4 hr at 37 °C. The MTT solution was then removed, and replaced with 100 µL of DMSO 
containing 4% aqueous ammonia per well to dissolve the purple formazan crystals. After 30 
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minutes, the absorbance of each well at 540 nm was recorded using a BioTek Synergy H1 
microplate reader. Control studies were also done using wells only containing bare MNPs and 
bare MNPs with tetrazine to confirm the inactivity of the tetrazine on the cells viability. All 
assays were done in triplicates or quadruplets.    
Results: To first show our MNPs conjugated with the dyes, as previously mentioned, we utilized 
the Chemi-doc imaging equipment. This clearly showed the correct ratiometric loading of our 
dyes in the various increasing and decreasing concentrations of our twos dyes, and confirmed the 
lack of background signal from the MNPs. This was consistent with our previous studies (N.M. 
Robertson, V.E. LaMantia, M. V. Yigit, submitted). We then set out to show specific release 
using tetrazine, characterizing this through HPLC. Our MNP-TCO construct was incubated with 
tetrazine to characterize how the dyes would release from the nanoparticle and in what 
timeframe. After numerous trials, we established that the molecule on the fast linker would 
release almost instantaneously, and all the compound was released by the 30-minute timeframe. 
The molecule on the slow linker released starting at 48 hours after tetrazine addition and was 
completed by 96 hours (N.M. Robertson, V.E. LaMantia, M. V. Yigit, submitted) This gave us 
vital quantitative information about the exact release characteristics, and further incentive to 
work with pharmacological agents that would benefit from the specific release kinetics to 
maximize our systems potential to treat resistant cancer phenotypes.  
Further studies were then done to look at this linker system in cell lines. Throughout this 
study, we used MDA-MB-231 triple negative breast cancer cell lines (TNBC). We initially 
wanted to look at cellular uptake and co-localization, to confirm that our MNPs were 
internalized, with confocal microscopy(N.M. Robertson, V.E. LaMantia, M. V. Yigit, 
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submitted). The overlay of both the FAM and TAMRA channels shows visually that both dyes 
are co-localized and internalized into the cells in an equal and partnered fashion in the same cell.  
We next looked to characterize different chemotherapeutic drugs with a capability to 
attach to our linker molecule. Numerous studies have been done looking at different drug 
combinations and their respective efficacy2,9,10,14. However, there remains a need for a truly 
efficient and patient independent system. Our first study was done using Doxorubicin (dox) and 
Gemcitabine. Unfortunately, gemcitabine can’t be view using UV/VIS technology as its 
absorbance peak is consistent with that of our MNPs and therefore can’t be distinguished when 
attached. We did however characterize our MNPs with dox on the fluorolog-3 to ensure there 
was no background signal given off by the MNPs. The drug and MNP mix was conjugated as 
described above, and purified through the column. As seen in Figure 1A, there is a clear increase 
in fluorescence with the MNPs loaded with dox at the expected wavelength of about 580 nm.  
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Figure 1: Fluorescent characterization of Dox and MNPs. A) On the left, we see the characterization 
of the MNPs alone, and then loaded with Dox. B) On the right, we see the ratiometric loading of Dox 
and Gemcitabine on MNPS, respectively. As the concentration of Dox increases we see an increased 
signal as expected.  
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We then further set out to show the ratiometric loading of a two-drug system in various 
concentrations to ensure equal loading onto the MNPs. While using dox and gemcitabine, we 
prepared the MNPs, washed them through a column as described above in ratiometric 
concentrations and then measured the fluorescence. Figure 1B depicts the loading of dox to 
gemcitabine, respectively, and shows that increasing the concentration of dox will show a higher 
fluorescent signal as expected.  While we can see dox fluoresce here, unfortunately gemcitabine 
does not have fluorescent capabilities. However, the chemistry and techniques are the same here 
as they were for the loading of the dyes, so we are confident we can load both drugs equally and 
efficiently. 
Once we proved we can link two payloads to our MNPs, and deliver, internalize, co-
localize, and sequentially control the release of these payloads, we designed experiments to test 
the toxicity of our system on these cells. After characterization of the chemotherapeutics, and 
synthesis of the MNP-drug combination, we tested these methods on TNBC cells. TNBC breast 
cells have specifically shown a weakness when treated with Doxorubicin, a DNA damaging 
chemotherapeutic, when coupled with an additional agent in a time staggered manner1,10. 
Without this time staggered manner, the TNBC cells are resistant to conventional 
chemotherapeutics such as Dox1. Additionally, Gemcitabine, known as a pyrimidine antagonist, 
is a cytidine analog that has shown promise in treating a variety of cancers, most specifically 
non-small cell lung cancer, pancreatic cancer and bladder cancer.  Its method of action in cells 
inhibits DNA replication by being converted into Gemcitabine 5′-diphosphate by active 
metabolites in the body. This compound inhibits ribonucleotide reductase, which is widely 
conserved across most species. Furthermore, the triphosphorylated derivative can become 
incorporated into the DNA, thus severely halting DNA synthesis15,16.  
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After displaying the click and release characteristics of the MNP-TCO-Drug constructs, 
we were then able to demonstrate this system in breast cancer cell lines to observe cell toxicity. 
Previously, studies were performed using PAC-1 and Doxorubicin as synergistic 
chemotherapeutic agents using the TCO linker system (N.M. Robertson, V.E. LaMantia, M. V. 
Yigit, submitted) and showed increased cell death in both BT-20 and MDA-MB-231 cell lines. 
Herein we look to expand on this knowledge and explore the effects of Gemcitabine and 
Doxorubicin. Control experiments were performed using just cells with no treatment, treatment 
with MNPs alone, treatment with tetrazine alone, and treatment with MNPs plus tetrazine. These 
studies showed limited cell toxicity as expected. We utilized different combinations of Dox and 
Gemcitabine, with different linkers, to explore which would have the best therapeutic effect on 
 
0
0.5
1
1.5
2
2.5
Control Control	+Tet MNPS MNPS	+	Tet Dox	slow Dox	fast Dox	Fast	Gem	Fast Dox	Slow	Gem	Fast Tet	32 Tet	8
Ab
s	5
40
Figure 2: MTT Assay of MDA-MB-231 cells under treatment of MNPs. This cell viability test shows 
the toxicity of various controls and treatments. The treatment of cells with MNPs or tetrazine (over 
both 32 and 8-hour time frames) shows little toxicity, while the combination of Dox-fast-TCO and 
Gemcitabine-fast-TCO shows high cell toxicity.  
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the MDA-MB-231 cells, with both the fast and slow TCO linkers. As seen in Figure 2, with Dox 
on the slow TCO linker and Gemcitabine on the fast TCO linker, cell death was minimal.  
However, when utilizing both Dox and Gemcitabine on fast TCO linkers we saw 
enhanced cell death compared to the alternative combinations and the single drugs alone. This 
shows the enhanced functionality of the TCO linker system and how it can be utilized in several 
different ways. Over the course of several trials of this experiment we saw the same trends, 
which can be seen in Figure 3.  
The average cell viability over the course of these trials, all conducted in triplicates or 
quadruplicates, was 61% for the Dox-fast and Gemcitabine-fast-TCO linkers. While our previous 
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Figure 3: Average cell viability after treatment. Over a course of trials the average of the data is 
shown. Treatment of any one of the controls shows a lack of cell death, while treatment with Dox-
fast-TCO and Gemcitabine-fast-TCO shows an average cell death of almost 40 %. This combination 
shows the dual activity of the drugs, and how it offers much greater treatment than just using the 
drugs alone.  
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literature (N.M. Robertson, V.E. LaMantia, M. V. Yigit, submitted) showed the best results 
utilizing the combination of slow and fast TCO linkers, our application using both the fast TCO 
linkers proved to be the best therapeutic treatment in this case.  
Conclusion: Herein we have described and demonstrated the workings of a novel system to treat 
resistant forms of breast cancer using biorthogonal chemistry and magnetic nanoparticles. The 
combination of these two allows for loading of two drugs onto our MNPs and sequential or dual 
controlled release using a single tetrazine trigger. By using the TCO system and choosing which 
payload we put on the di-axial (fast) position or di-equatorial (slow) position, we can control the 
kinetics of the release. This allows for a controllable, systematic approach to treatment. We have 
outlined the loading of dyes on MNPs to characterize the TCO system, measured the release of 
these dyes through HPLC to show kinetics and imaged the fluorescence uptake of the MNPs in 
vitro. We then characterized two additional drug combinations that could be used to treat these 
phenotypically resistant cancer types, after initially showing the system in a different study 
(N.M. Robertson, V.E. LaMantia, M. V. Yigit, submitted). This system was shown to be 
effective to treat TNBC cell lines, which have been shown to be resistant to conventional 
treatments. This single trigger, duel release system has been shown to be effective for this 
treatment type, but ultimately holds promise in many other aspects of medicine because of the 
novel capability to load a variety of things onto the TCO linker system. This new approach offers 
a way to simultaneously or sequentially give treatment in a controlled and systematic way that 
was not before possible.  
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Supplemental Information: 
Nanoparticle Synthesis: The dextran coated superparamagnetic iron oxide nanoparticles were 
synthesized according to our previous reports (N.M. Robertson, V.E. LaMantia, M. V. Yigit, 
submitted) Briefly, 18 g of Dextran-T10 (Pharmacosmos, Holbaek, Denmark) was mixed with 
60 mL of double-distilled water and stirred in a round bottom flask in an ice bath until dissolved 
completely. 1.3 g of FeCl3.6H2O (Sigma Aldrich) was added into the clear dextran suspension 
while flushing Argon gas into the reaction mixture. 0.8 g of FeCl2·4H2O (Sigma Aldrich) was 
dissolved in 5 mL of distilled water, which was previously flushed with Argon gas in order to 
avoid oxidation, and immediately added into the reaction mixture. 30 mL of concentrated cold 
NH4OH (~28%) was added to the stirring homogenous mixture and the temperature was 
increased to 75-85 °C for an hour. The mixture was cooled to room temperature afterwards and 
concentrated to 40 mL using Amicon Ultra centrifugal units (MWCO 100 kDa; Millipore, 
Billerica, MA, USA). The dextran coating on the nanoparticles was cross-linked with the 
addition of 70 mL of concentrated NaOH (5 M) and 20 mL of concentrated epichlorohydrin 
(Sigma-Aldrich) and the mixture was stirred for 8 hours. Later, the nanoparticles were aminated 
by the addition of 120 mL of concentrated NH4OH (~28%, Sigma-Aldrich) into the mixture and 
stirred for an additional 24 hr in the hood. The nanoparticle solution was purified using a dialysis 
bag (MWCO 14 kDa, SpectrumLabs, Dominguez, CA) against distilled water and finally 
suspended in 20 mM sodium citrate buffer (pH 8.0). The nanoparticle concentration was 
determined based on iron concentration, measured by UV-vis spectroscopy and adjusted to be 
~10.0 mg Fe/mL.4 
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Trans-Cyclooctene (TCO) Synthesis and Chemical Conjugation.  
The NHS-TCOfast-NHS and NHS-TCOslow-NHS bioorthogonal TCO linkers utilized to 
immobilize the payloads on the MNP were synthesized according to the procedure described in 
the literature.17  
Synthesis of TAMRA-TCOfast-NHS: TAMRA was synthesized based on the previously 
reported procedure.18 The TAMRA (0.11 mmol) was combined with NHS-TCOfast-NHS (0.11 
mmol) in DMF (2 mL), in the presence of triethylamine (100 µL). The reaction mixture was 
stirred for 18 hr at room temperature under N2. DMF was removed under high vacuum and the 
crude product was redissolved in CH2Cl2 (3 mL). The title product (TAMRA-TCOfast-NHS) was 
obtained upon purification using preparatory SiO2 TLC using a 9:1 mixture of CH2Cl2 and 
MeOH, containing 2% triethylamine as a mobile phase. Yield = 50 mg (58 %).  
Synthesis of FAM-TCOslow-NHS: The FAM was synthesized based on the previously reported 
procedure.19 The FAM (0.17 mmol) was combined with the NHS-TCOslow-NHS (0.17 mmol) in 
DMF (4 mL), in the presence of triethylamine (200 µL). The reaction mixture was stirred for 18 
hr at room temperature under N2. DMF was removed under high vacuum and the crude product 
was redissolved in MeOH (3 mL). The title product (FAM-TCOslow-NHS) was obtained upon 
purification using preparatory SiO2 TLC using a 9:1 mixture of CH2Cl2 and MeOH as a mobile 
phase. Yield = 65 mg (54 %).  
Synthesis of DOX-TCOslow-NHS: The compound doxorubicin (0.15 mmol) was combined 
with the NHS-TCOslow-NHS (0.15 mmol) in DMF (4 mL), in the presence of triethylamine (101 
µL). The reaction mixture was stirred for 18 hr at room temperature under N2. DMF was 
removed under high vacuum and the crude product was redissolved in CH2Cl2 (3 mL). The title 
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product (DOX-TCOslow-NHS) was obtained upon purification using preparatory SiO2 TLC using 
a 9:1 mixture of CH2Cl2 and MeOH as a mobile phase. Yield = 77 mg (60 %).  
Synthesis of Gemcitabine-TCOfast-NHS: To a solution of Gemcitabine (50 mg, 0.19 mmol) in 
pyridine (5 mL) was added and TCO-bis NHS ester (80 mg, 0.19 mmol). The solution was 
stirred at room temperature for 18 hours. The reaction was quenched with H2O and concentrated 
to dryness under reduced pressure. The residue was dissolved in DCM and washed with 5% 
citric acid solution and brine. The organic layer was dried over Na2SO4 and purified by flash 
silica gel column chromatography (5 % MeOH in DCM). The title product was obtained as a 
white solid. Yield = 59 mg (55%). 
Synthesis of tetrazine: Isobutyronitrile (10 mmol) and zinc triflate (0.5 mmol) were combined 
with anhydrous hydrazine (1.6 mL) and stirred at 60 ºC for 24 hr under N2. The reaction mixture 
was diluted with DMF (2 mL). An aqueous solution of NaNO2 (3.5 g in 50 mL) was slowly 
added. Inside a thoroughly ventilated fume hood, an aqueous 2M solution of HCl was added 
slowly until reaching pH~3. (Caution! The last step generates highly toxic fumes, containing 
reactive nitrogen species.) The product was extracted with CH2Cl2 (3x100 mL), dried with 
Na2SO4 and concentrated. The title product was obtained by chromatography using 1% Et2O in 
pentane (1.2 g, 72%). 1H NMR (CDCl3, 400 MHz) δ: 3.62 (sep, J = 6.8 Hz, 2H), 1.51 (d, J = 6.9 
Hz, 12H). 13C{1H} NMR (CDCl3, 100 MHz) δ: 173.69, 34.14, 21.22. HRMS (DART) m/z:  
calcd. for C8H15N4 [M+1]+ 167.1297; found 167.1306. 
Nanoparticle Conjugation: The amine terminated iron oxide nanoparticles (MNPs) were 
functionalized with NHS modified molecular cargoes as follows. For the conjugation of the 
small molecule dyes, 250 µL of stock MNPs (7.2 mg Fe/mL, 64 μM) was added to 750 µL of 
citrate buffer (20 mM Na-Citrate, 150 mM NaCl, pH 8.2). 100 µL of this mixture was then 
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combined with another 50 µL of citrate buffer and the TAMRA-TCO-NHS and FAM-TCO-NHS 
in a ratio out of 10 µL (0:10, 1:9, 3:7, 5:5, 7:3, 9:1 and 10:0 µL from 10 mM stocks) for a final 
volume of 160 µL and MNP concentration of 1.125 mg Fe/mL (10 μM). These mixtures were 
incubated in the dark at room temperature for 24 hr and purified afterwards with Sephadex PD-
10 columns against PBS buffer. The nanoparticle band in the column was collected whereas the 
free unconjugated dye band was discarded. For characterization of the dye conjugated MNPs 
[FAM-TCOslow-MNP-TCOfast-TAMRA, (MNP-FsTf)], the absorbance spectra were measured 
and standardized to the Abs360 of the bare MNP solution. For the conjugation of the small 
molecule drugs, 250 µL of stock MNPs (7.2 mg Fe/mL) was added to 250 µL of citrate buffer. 
To this mixture, 50 µL of the 10 mM stock aqueous solutions of each drug conjugate, DOX-
TCOslow-NHS and PAC1-TCOfast-NHS, was added individually or in combination to obtain 
various MNP-TCO variations: [DOX-TCOslow-MNP-TCOfast-PAC1, (MNP-DsPf)], [MNP-
TCOfast-DOX, (MNP-Df)] and [MNP-TCOfast-PAC1, (MNP-Pf)] at a final volume of 600 µL. 
An additional 50 µL of citrate buffer was added to each mixture when necessary to obtain 600 
µL. After 24 hours of incubation in the dark at room temperature the conjugated MNPs were 
purified with Sephadex PD-10 columns against PBS buffer and the concentration was adjusted to 
be 1.2 mg Fe/mL (10.7 μM) using PBS buffer for in vitro studies. 
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